Loading...

Brilliant Violet 421™ anti-human CD14 Antibody

Pricing & Availability
Clone
M5E2 (See other available formats)
Regulatory Status
RUO
Workshop
III 329
Other Names
LPS receptor
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
M5E2_BV421_062311
Human peripheral blood monocytes were stained with CD14 (clone M5E2) Brilliant Violet 421™ (filled histogram) or mouse IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).
  • M5E2_BV421_062311
    Human peripheral blood monocytes were stained with CD14 (clone M5E2) Brilliant Violet 421™ (filled histogram) or mouse IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).
See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
301829 25 tests 164€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
301830 100 tests 322€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD14 is a 53-55 kD glycosylphosphatidylinositol (GPI)-linked membrane glycoprotein also known as LPS receptor. CD14 is expressed at high levels on monocytes and macrophages, and at lower levels on granulocytes. Some dendritic cell populations such as interfollicular dendritic cells, reticular dendritic cells, and Langerhans cells have also been reported to express CD14. As a high-affinity receptor for LPS, CD14 is involved in the clearance of gram-negative pathogens, and in the upregulation of adhesion molecules and expression of cytokines in monocytes and neutrophils.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human,Cynomolgus,Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Full-length human CD14 protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The M5E2 antibody inhibits monocyte activation and cytokine production induced by LPS. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections, blocking of LPS stimulation4, and immunofluorescence microscopy5. Clone M5E2 is not recommended for immunohistochemical staining of formalin-fixed paraffin-embedded sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 301861 and 301862).

Application References
  1. McMichael A, et al. 1987. Leucocyte Typing III. Oxford University Press. New York.
  2. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York. (IHC-F)
  3. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  4. Power CP, et al. 2004. J. Immunol. 173:5229. (Block)
  5. Williams KC, et al. 2001. J. Exp. Med. 193:905.
  6. Iwamoto S, et al. 2007. J. Immunol. 179:1449. (FC) PubMed
  7. Santer DM, et al. 2010. J. Immunol. 485:4739. PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Zizzo G, et al. 2012. J. Immunol. 189:3508. PubMed
  10. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  11. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Li C, et al. 2017. Virulence. 8:1833. PubMed
  2. Wu Q, et al. 2018. Mol Med Rep. 18:564. PubMed
  3. Willingham SB, et al. 2018. Cancer Immunol Res. 6:1136. PubMed
  4. Haynes A, et al. 2018. J Appl Physiol (1985). 125:401. PubMed
  5. Tomellini E, et al. 2020. Cell Reports. 28(4):1063-1073.e5.. PubMed
  6. Kong R, et al. 2019. Cell. 178:567. PubMed
  7. Teijeira á, et al. 2020. Immunity. 52(5):856-871. PubMed
  8. Cheng C, et al. 2020. Cell Reports. 32(5):107981. PubMed
  9. Rainho J, et al. 2015. J Virol. 89: 10625 - 10636. PubMed
  10. Norton S, et al. 2016. Clin Transl Immunology. 5: e76. PubMed
  11. Gadd V, et al. 2016. PLoS One. 11: 0157771. PubMed
  12. Haynes A, et al. 2016. Physiol Rep. 4: e12951. PubMed
  13. Siedlik J, et al. 2017. J Immunol Methods. 10.4049/jimmunol.1700003. PubMed
  14. Silvin A, et al. 2020. Cell. 182:1401. PubMed
  15. Laing AG, et al. 2020. Nat Med. 26:1623. PubMed
  16. Evren E, et al. 2020. Immunity. 54(2):259-275.e7. PubMed
  17. Vierboom MPM, et al. 2021. Cell Reports Medicine. 2(1):100185. PubMed
  18. Juul-Madsen K, et al. 2020. J Immunol. 1345:204. PubMed
  19. Cui D, et al. 2021. Front Cell Dev Biol. 9:656867. PubMed
  20. Sabree SA, et al. 2021. J Immunother Cancer. 9: . PubMed
  21. Buters TP, et al. 2021. Br J Clin Pharmacol. Online ahead of print. PubMed
  22. van der Wijst MGP, et al. 2021. Sci Transl Med. 13:eabh2624. PubMed
  23. Pinkert J, et al. 2022. Oncoimmunology. 11:2008110. PubMed
  24. Maheshwari D, et al. 2022. iScience. 25:104384. PubMed
  25. Lende SSF, et al. 2022. Front Cell Infect Microbiol. 12:919097. PubMed
  26. Ronaghan NJ, et al. 2022. PLoS One. 17:e0276013. PubMed
  27. Porbahaie M, et al. 2022. Nutrients. 14:. PubMed
  28. Baharlou H, et al. 2022. Cell Rep. 40:111385. PubMed
  29. Sugrue JA, et al. 2022. Cell Rep Med. 3:100804. PubMed
  30. Wali G, et al. 2023. Front Neurosci. 17:1073516. PubMed
RRID
AB_10899407 (BioLegend Cat. No. 301829)
AB_10959324 (BioLegend Cat. No. 301830)

Antigen Details

Structure
GPI-linked membrane glycoprotein, 53-55 kD
Distribution

Monocytes, macrophages, granulocytes (low)

Function
LPS receptor, clearance of Gram-negative pathogens
Ligand/Receptor
LPS
Cell Type
Granulocytes, Macrophages, Monocytes, Neutrophils
Biology Area
Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience
Molecular Family
CD Molecules
Antigen References

1. Stocks S, et al. 1990. Biochem. J. 268:275.
2. Wright S, et al. 1990. Science 249:1434.

Gene ID
929 View all products for this Gene ID
UniProt
View information about CD14 on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Go To Top Version: 4    Revision Date: 11.05.2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account